VEMURAFENIB EFFECTIVE IN NSCLC WITH BRAF-V600 MUTATIONS BUT NOT BRAF NON-V600 MUTATIONS

The authors of this report provide data from a prospective trial to evaluate the benefit of vemurafenib monotherapy for non small cell lung cancer (NSCLC) patients with BRAF-V600 and non-V600 mutations. In the V600 cohort, 43 of 96 patients experienced an objective response, but there were no responses for those with non-V600 mutations.

Vemurafenib monotherapy has efficacy in NSCLC patients with BRAF-V600 mutations and not in those with non-V600 mutations. Biomarker screening should include BRAF V600 mutations.

https://www.practiceupdate.com/c/95016/1/1/?elsca1=emc_enews_expert-insight&elsca2=email&elsca3=practiceupdate_onc&elsca4=oncology&elsca5=newsletter&rid=NjI5MDUyOTgwNDYS1&lid=10332481